Onconic Therapeutics Unveils Drug Candidate for "Muscle Preservation" with Obesity Treatments
Study on preserving skeletal muscle during semaglutide-induced weight loss
Combination strategy, not an alternative to GLP-1... targets body composition improvements beyond weight loss
To be presented at ObesityWeek in November
Onconic Therapeutics has for the first time unveiled OCN-501, a novel drug candidate designed to preserve skeletal muscle during weight loss when used in combination with obesity treatments.
Onconic Therapeutics said on October 12 that its study of OCN-501 had been accepted for the public abstracts of ObesityWeek 2026, the annual scientific meeting of The Obesity Society, to be held in Washington, D.C., in November, and had also been selected for an oral presentation session. The study is titled “First-in-Class OCN-501 for Preserving Skeletal Muscle During Semaglutide-Induced Weight Loss.”
OCN-501 is being developed for use in combination with GLP-1 obesity treatments, including semaglutide, the active ingredient in Wegovy. One challenge associated with GLP-1 treatments is that weight loss can reduce not only fat but also lean body mass and muscle mass. Accordingly, combination treatment strategies that preserve muscle and improve body composition while maintaining weight-loss effects are drawing attention.
Eli Lilly, the developer of Mounjaro, has also identified combination treatments with GLP-1 and incretin therapies, as well as improvements in body composition, including the preservation or increase of lean body mass, as areas of interest for business development.
Building on its experience commercializing Zaqbo, a treatment for gastroesophageal reflux disease, and developing nesuparib, an anticancer drug candidate, Onconic Therapeutics plans to develop OCN-501 as a next-generation global drug pipeline asset.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Onconic Therapeutics representative said, “We are developing it with the strategic goal of creating new therapeutic value through combination treatment with GLP-1 therapies, which have already established a massive market.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.